Oliver Engert Buys 1,000 Shares of Enovis (NYSE:ENOV) Stock

Enovis Corporation (NYSE:ENOV) insider Oliver Engert purchased 1,000 shares of the firm’s stock in a transaction on Wednesday, June 10th. The shares were acquired at an average cost of $23.00 per share, for a total transaction of $23,000.00. Following the completion of the purchase, the insider directly owned 50,640 shares of the company’s stock, valued at approximately $1,164,720. This represents a 2.01% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Oliver Engert also recently made the following trade(s):

• On Monday, June 1st, Oliver Engert purchased 1,000 shares of Enovis stock. The shares were acquired at an average cost of $22.22 per share, for a total transaction of $22,220.00.
• On Friday, March 13th, Oliver Engert purchased 1,000 shares of Enovis stock. The shares were acquired at an average cost of $23.74 per share, for a total transaction of $23,740.00.

Enovis Trading Up 2.7%

ENOV stock opened at $21.70 on Friday. The company has a market capitalization of $1.25 billion, a PE ratio of -1.09 and a beta of 1.38. Enovis Corporation has a one year low of $20.55 and a one year high of $36.82. The company’s 50 day moving average price is $24.03 and its two-hundred day moving average price is $24.60. The company has a debt-to-equity ratio of 0.87, a quick ratio of 1.05 and a current ratio of 2.04.

Enovis (NYSE:ENOV) last posted its quarterly earnings results on Thursday, May 7th. The company reported $0.89 EPS for the quarter, topping the consensus estimate of $0.82 by $0.07. The firm had revenue of $589.15 million for the quarter, compared to the consensus estimate of $572.02 million. Enovis had a negative net margin of 49.92% and a positive return on equity of 10.32%. The business’s revenue was up 5.4% compared to the same quarter last year. During the same period last year, the firm posted $0.81 earnings per share. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. As a group, analysts predict that Enovis Corporation will post 3.65 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Enovis

A number of hedge funds have recently bought and sold shares of ENOV. Arax Advisory Partners purchased a new position in Enovis in the 4th quarter worth about $29,000. EverSource Wealth Advisors LLC raised its position in Enovis by 125.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock worth $40,000 after buying an additional 707 shares during the last quarter. GAMMA Investing LLC raised its position in Enovis by 353.5% in the 4th quarter. GAMMA Investing LLC now owns 1,855 shares of the company’s stock worth $49,000 after buying an additional 1,446 shares during the last quarter. Danske Bank A S purchased a new position in Enovis in the 3rd quarter worth about $64,000. Finally, iSAM Funds UK Ltd purchased a new position in Enovis in the 3rd quarter worth about $80,000. Hedge funds and other institutional investors own 98.45% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on the stock. Wells Fargo & Company decreased their target price on shares of Enovis from $42.00 to $40.00 and set an “overweight” rating on the stock in a research note on Friday, May 8th. Wall Street Zen downgraded shares of Enovis from a “buy” rating to a “hold” rating in a research note on Saturday, June 6th. William Blair initiated coverage on shares of Enovis in a report on Friday, April 17th. They issued an “outperform” rating on the stock. Zacks Research lowered Enovis from a “strong-buy” rating to a “hold” rating in a research report on Monday, June 1st. Finally, Evercore reaffirmed an “outperform” rating and issued a $36.00 price target on shares of Enovis in a research report on Friday, May 8th. Seven analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $44.50.

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.